Short answer

Bio-rad Laboratories Inc (BIO) filed its fiscal 2012 10-K annual report with the SEC on Mar 18, 2013.

Top risk flagged: FCPA investigation: DOJ and SEC pursuing potential overseas violations, with possible fines, disgorgement, monitors and business restrictions

Bio-rad Laboratories Inc FY2012 10-K analysis

AI summary of each section, grounded in the filing text

Global life sciences and diagnostics supplier, monetizing research tools and recurring clinical testing consumables
Two segments: Life Science 33% and Clinical Diagnostics 66% of 2012 net sales
International emphasis: 68% of sales outside the U.S., with direct distribution in over 35 countries
R&D investment rose to $214.0 million from $186.4 million in 2011
Approximately 7,380 employees, including 1,000 worldwide sales and service personnel

Revenue $2.07B, flat YoY; currency-neutral sales up 3.6%
Clinical Diagnostics best segment: $1.37B sales, up 0.1%; Life Science worst: $688.4M, down 0.9%
Gross margin 55.8% vs 56.8%; net-income margin 7.9% vs 8.6%; effective tax rate 27% vs 24%
Operating cash flow $278.9M; capex $152.4M; cash, equivalents and short-term investments $921.1M
No 2012 buybacks beyond 1,039 shares for employee tax obligations; risks include government spending constraints and sovereign customer payment delays

FCPA investigation: DOJ and SEC pursuing potential overseas violations, with possible fines, disgorgement, monitors and business restrictions
Sovereign-credit exposure: Accounts receivable in Spain, Italy, Greece and Portugal totaled $64.8 million at December 31, 2012
Control weakness: Four significant deficiencies created a material weakness in financial reporting, including German and Chinese subsidiary issues
Regulatory reimbursement pressure: PPACA mandates a 1.75% Medicare Clinical Laboratory Fee Schedule reduction through 2015
Debt burden: $734.2 million outstanding indebtedness, with 8% Senior Subordinated Notes due 2016

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.